title: [Neoadjuvant therapy for operable breast-cancer].
abstract: Preoperative or neoadjuvant systemic treatment refers to either the first postdiagnosis systemic treatment that a patient receives or indicates that additional subsequent therapy is intended. Randomized controlled clinical trials have shown that preoperative systemic treatment offers the same disease free survival and overall survival benefits as does adjuvant systemic treatment. Neoadjuvant therapy has been found to increase the breast-conserving surgery rate. This therapy also allows to evaluate the primary tumor response to chemotherapy. Additionally, on the basis of the biologic characteristics of a tumor and differences in the response to systemic treatment, primary systemic treatment should be regarded as a tool that can be used to individualize systemic treatment for patients with breast cancer. However, some issues remain to be resolved, such as the markers that should be assessed before this therapy, as well as the optimal surgical and radiotherapy treatment.
authors.affiliation: Servicio de Hematología y Oncología Médica, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain.
authors.forename: Amelia
authors.initials: A
authors.lastname: Insa
authors.forename: Isabel
authors.initials: I
authors.lastname: Chirivella
authors.forename: Ana
authors.initials: A
authors.lastname: Lluch
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D011300:Preoperative Care; D016032:Randomized Controlled Trials as Topic